Liquidia-2026-JPM.pdf

1、2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVEDCorporate OverviewJ.P.Morgan Healthcare Conference 2026January 14,202622026 LIQUIDIA CORPORATION ALL RIGHTS RESERVEDForward-looking statementsThis presentation includes,and our response to questions may include,forward-looking statements within the meanin

2、g of the Private Securities Litigation Reform Act of 1995(“PSLRA”).All statements contained in this presentation other than statements of historical facts,including statements regarding our future results of operations and financial position,our strategic and financial initiatives,our business strat

3、egy and plans and our objectives for future operations,are forward looking statements.Such forward-looking statements,including statements regarding clinical trials,clinical studies and other clinical work(including the funding therefor,anticipated patient enrollment,safety data,study data,trial out

4、comes,timing or associated costs),regulatory applications and related submission contents and timelines,the timelines or outcomes related to patent litigation with United Therapeutics in the U.S.District Court for the District of Delaware and U.S.District Court for the Middle District of North Carol

5、ina,or other litigation between Liquidia and United Therapeutics or others,including rehearings or appeals of decisions in any such proceedings,the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives,the potential for additional funding under the HCR

6、 Agreement,our anticipated use of net proceeds funded under the HCR Agreement,our estimates regarding future expenses,capital requirements and needs for additional financing,and potential revenue and profitability of YUTREPIA involve significant risks and uncertainties and actual results could diffe